Akero Therapeutics, Inc. Retained Earnings
Akero Therapeutics, Inc. had Retained Earnings of -$1.05 billion as of 2025-09-30, per its 10-Q filed 2025-11-07.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2025-11-07
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$1.05B.
- 2025-06-30: Retained Earnings (Accumulated Deficit) -$967.39M.
- 2025-03-31: Retained Earnings (Accumulated Deficit) -$896.88M.
- 2024-12-31: Retained Earnings (Accumulated Deficit) -$826.16M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2025-09-30 | -$1.05B 10-Q · filed 2025-11-07 |
| 2025-06-30 | -$967.39M 10-Q · filed 2025-08-08 |
| 2025-03-31 | -$896.88M 10-Q · filed 2025-05-12 |
| 2024-12-31 | -$826.16M 10-Q · filed 2025-11-07 |
| 2024-09-30 | -$756.13M 10-Q · filed 2024-11-08 |
| 2024-06-30 | -$683.43M 10-Q · filed 2024-08-09 |
| 2024-03-31 | -$627.44M 10-Q · filed 2024-05-10 |
| 2023-12-31 | -$574.10M 10-K · filed 2025-02-28 |
| 2023-09-30 | -$518.91M 10-Q · filed 2023-11-13 |
| 2023-06-30 | -$479.25M 10-Q · filed 2023-08-11 |
| 2023-03-31 | -$448.17M 10-Q · filed 2023-05-15 |
| 2022-12-31 | -$422.34M 10-K · filed 2024-02-29 |
| 2022-09-30 | -$399.28M 10-Q · filed 2022-11-04 |
| 2022-06-30 | -$363.74M 10-Q · filed 2022-08-05 |
| 2022-03-31 | -$336.33M 10-Q · filed 2022-05-06 |
| 2021-12-31 | -$310.30M 10-K · filed 2023-03-17 |
| 2021-09-30 | -$277.88M 10-Q · filed 2021-11-12 |
| 2021-06-30 | -$253.55M 10-Q · filed 2021-08-13 |
| 2021-03-31 | -$224.62M 10-Q · filed 2021-05-13 |
| 2020-12-31 | -$209.53M 10-K · filed 2022-02-25 |
| 2020-09-30 | -$179.82M 10-Q · filed 2020-11-12 |
| 2020-06-30 | -$158.41M 10-Q · filed 2020-08-12 |
| 2020-03-31 | -$142.21M 10-Q · filed 2020-05-13 |
| 2019-12-31 | -$130.32M 10-K · filed 2021-03-16 |
| 2019-09-30 | -$114.71M 10-Q · filed 2019-11-12 |
| 2019-06-30 | -$99.16M 10-Q · filed 2019-08-12 |
| 2018-12-31 | -$86.56M 10-K · filed 2020-03-16 |